focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Summit Corporation Completes Fund Raising With Over-Subscribed Subscription

Wed, 26th Feb 2014 11:40

LONDON (Alliance News) - Summit Corporation Wednesday said it raised gross proceeds of GBP1.0 million in an oversubscribed subscription offer, meaning it raised GBP22.0 million through its recent placing and the subscription.

In a statement, Summit said it had to scale back allocations after the subscription offer was more than seven times over-subscribed.

Oxford-nased Summit is a drug discovery and development company working on therapies for Duchenne Muscular Dystrophy and C. difficile infection.

It conducted its GBP21.0 million placing February 11.

Summit Corporation shares were up 2.9% at 8.75 pence Wednesday morning.

By Steve McGrath; stevemcgrath@alliancenews.com; @SteveMcGrath1

Copyright © 2014 Alliance News Limited. All Rights Reserved.

More News
12 Feb 2015 16:47

UK AGM, EGM Calendar - Week Ahead

Read more
2 Feb 2015 11:05

REPEAT: Summit Corp Plans Dual NASDAQ Listing, Name Change As Loss Widens (ALLIPO)

Read more
2 Feb 2015 09:38

Summit Corp Plans Dual NASDAQ Listing, Name Change As Loss Widens

Read more
8 Oct 2014 07:48

Summit Reports Positive Data At World Muscle Society Congress

Read more
8 Sep 2014 08:24

Summit Corp Says Studies Show Its SMT19969 Superior To Vancomycin

Read more
4 Sep 2014 09:58

Summit Corp Widens Loss As It Progresses Drugs Through Trials

Read more
30 Jul 2014 16:48

Summit chief buys 30,000 shares

AIM-listed drug developer Summit, which develops therapies for Duchenne Muscular Dystrophy and C. difficile infection, on Wednesday said its chief executive Glyn Edwards had acquired 30,000 shares. The 104.5p-a-share deal cost Edwards £31,350 and took his stake in the group to 233,333 shares. The

Read more
9 Jul 2014 07:37

UK MORNING BRIEFING: Deutsche Bank Raises Shell View, Cuts BP

Read more
7 Jul 2014 08:10

Summit Sees Positive Duchenne Muscular Dystrophy Drug Trial Results

Read more
3 Jul 2014 08:25

Summit Says First Patients In Phase II Antibiotic Trial Dosed

Read more
3 Jul 2014 07:33

UK MORNING BRIEFING: Tullow Oil Strikes Oil Offshore Norway

Read more
23 Jun 2014 07:27

UK MORNING BRIEFING: Shares Down As Iraq Fighting Lifts Oil Prices

Read more
23 Jun 2014 06:52

Summit Corp Appoints Erik Ostrowski As Chief Financial Officer

Read more
3 Jun 2014 08:52

Summit Corp To Consolidate Share Capital, Hoping To Get New Investors

LONDON (Alliance News) - Summit Corporation PLC Tuesday said it will seek shareholder permission for a share consolidation that will see every 20 existing shares consolidated into one new share. In a statement, the drug discovery company said it will first consolidate every 20 shares into o

Read more
21 May 2014 12:43

Summit Corp. reports progress with DMD trial, but next phase delayed

Shares in Summit Corporation suffered a fall despite giving a generally positive report of the first phase of its Duchenne Muscular Dystrophy (DMD) trial which has examined the safety and tolerance of SMT C1100. The decline may be linked to a delay in the next patient study, which is expected to no

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.